File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cyclosporin A for persistent or chronic immune thrombocytopenia in children

TitleCyclosporin A for persistent or chronic immune thrombocytopenia in children
Authors
KeywordsChronic
Cyclosporin
Immune thrombocytopenia
Pediatric
Issue Date2016
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htm
Citation
Annals of Hematology, 2016, v. 95, p. 1881-1886 How to Cite?
AbstractTwenty percent of children with immune thrombocytopenia (ITP) develop a chronic course where treatment strategy is less established. Cyclosporin A (CSA) has been shown to be effective in small series of children with chronic ITP and might reduce the need for chronic steroid therapy and/or splenectomy. We reviewed consecutive patients below 18 years old with persistent or chronic ITP treated with CSA in our unit between January 1998 and June 2015. Thirty patients (14 boys and 16 girls) were included. The median age at initial diagnosis of ITP was 5 years (range 0.5–16.2 years). CSA was started at a median of 13.9 months (range 3.4–124 months) after initial diagnosis and given for a median duration of 9.3 months (range 0.2–63.9 months). The median platelet count before commencement was 12 × 109/L (range 4–199 × 109/L). The median dose of CSA was 6 mg/kg/day (range 2.4–7.5 mg/kg/day). Complete response (CR) or response (R) was achieved in 17 patients (57 %), and 7 (23 %) had sustained response. Side effects (most commonly hirsutism) were tolerable and reversible. CSA appeared effective in about half of persistent or chronic ITP patients and safe as a second-line agent in managing these children.
Persistent Identifierhttp://hdl.handle.net/10722/229364
ISSN
2023 Impact Factor: 3.0
2023 SCImago Journal Rankings: 0.912
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiu, APY-
dc.contributor.authorCheuk, DKL-
dc.contributor.authorLee, AHY-
dc.contributor.authorLee, PPW-
dc.contributor.authorChiang, AKS-
dc.contributor.authorHa, SY-
dc.contributor.authorTsoi, WC-
dc.contributor.authorChan, GCF-
dc.date.accessioned2016-08-23T14:10:42Z-
dc.date.available2016-08-23T14:10:42Z-
dc.date.issued2016-
dc.identifier.citationAnnals of Hematology, 2016, v. 95, p. 1881-1886-
dc.identifier.issn0939-5555-
dc.identifier.urihttp://hdl.handle.net/10722/229364-
dc.description.abstractTwenty percent of children with immune thrombocytopenia (ITP) develop a chronic course where treatment strategy is less established. Cyclosporin A (CSA) has been shown to be effective in small series of children with chronic ITP and might reduce the need for chronic steroid therapy and/or splenectomy. We reviewed consecutive patients below 18 years old with persistent or chronic ITP treated with CSA in our unit between January 1998 and June 2015. Thirty patients (14 boys and 16 girls) were included. The median age at initial diagnosis of ITP was 5 years (range 0.5–16.2 years). CSA was started at a median of 13.9 months (range 3.4–124 months) after initial diagnosis and given for a median duration of 9.3 months (range 0.2–63.9 months). The median platelet count before commencement was 12 × 109/L (range 4–199 × 109/L). The median dose of CSA was 6 mg/kg/day (range 2.4–7.5 mg/kg/day). Complete response (CR) or response (R) was achieved in 17 patients (57 %), and 7 (23 %) had sustained response. Side effects (most commonly hirsutism) were tolerable and reversible. CSA appeared effective in about half of persistent or chronic ITP patients and safe as a second-line agent in managing these children.-
dc.languageeng-
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htm-
dc.relation.ispartofAnnals of Hematology-
dc.rightsThe final publication is available at Springer via http://dx.doi.org/[insert DOI]-
dc.subjectChronic-
dc.subjectCyclosporin-
dc.subjectImmune thrombocytopenia-
dc.subjectPediatric-
dc.titleCyclosporin A for persistent or chronic immune thrombocytopenia in children-
dc.typeArticle-
dc.identifier.emailLiu, APY: apyliu@hku.hk-
dc.identifier.emailLee, PPW: ppwlee@hku.hk-
dc.identifier.emailChiang, AKS: chiangak@hku.hk-
dc.identifier.emailChan, GCF: gcfchan@hku.hk-
dc.identifier.authorityLiu, APY=rp01357-
dc.identifier.authorityLee, PPW=rp00462-
dc.identifier.authorityChiang, AKS=rp00403-
dc.identifier.authorityChan, GCF=rp00431-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00277-016-2791-y-
dc.identifier.pmid27525725-
dc.identifier.scopuseid_2-s2.0-84982144127-
dc.identifier.hkuros262723-
dc.identifier.volume95-
dc.identifier.spage1881-
dc.identifier.epage1886-
dc.identifier.isiWOS:000387353500016-
dc.publisher.placeGermany-
dc.identifier.issnl0939-5555-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats